SCHEMBL5803080

SCHEMBL5803080

COc1ccc(C)cc1OS(=O)(=O)c1cc(CN2CCN(C)CC2)c2occc2c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.39
MTNR1A P48039 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
POLB P06746 1/20 0.38
ALDH1A1 P00352 2/20 0.37
PKM P14618 1/20 0.37
SOS1 Q07889 1/20 0.37
KDM4E B2RXH2 1/20 0.36
STAT3 P40763 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5817877 0.93 KCNJ1 (0.38) HTR6MTNR1AMEN1KMT2ATP53
SCHEMBL5803075 0.90 HTR6 (0.43) HTR6MEN1KMT2ATP53SMN1; SMN2
SCHEMBL5820171 0.87 HTR6 (0.41) HTR6MEN1KMT2AALDH1A1PKM
SCHEMBL5807018 0.84 HTR6 (0.39) HTR6KMT2AKDM4E
SCHEMBL5823362 0.84 HTR6 (0.39) HTR6KMT2AKDM4E
SCHEMBL5803553 0.84 HTR6 (0.39) HTR6KMT2AKDM4E
Trifluoroacetic Acid SCHEMBL5819999 0.83 HTR6 (0.38) HTR6ALDH1A1PKMSOS1
Trifluoroacetic Acid SCHEMBL5820633 0.81 HTR6 (0.37) HTR6PKMSOS1
Trifluoroacetic Acid SCHEMBL5820047 0.79 HTR6 (0.35) HTR6KMT2AKDM4E
Trifluoroacetic Acid SCHEMBL5817999 0.79 HTR6 (0.35) HTR6KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060142269-A1 New compounds BIOVITRUM AB (SE) 2006-06-29 US claimed
WO-2006062481-A1 NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . BIOVITRUM AB (SE) 2006-06-15 WO claimed
US-20060142269-A1 New compounds BIOVITRUM AB (SE) 2006-06-29 US disclosed
WO-2006062481-A1 NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . BIOVITRUM AB (SE) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142269-A1 New compounds GPR119, GLP1R, IAPP HTR6 932/4885MTNR1A 45/4885MEN1 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.